BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Cigrovski Berkovic M, Rezic T, Bilic-Curcic I, Mrzljak A. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum? World J Clin Cases 2022; 10(20): 6759-6768 [PMID: 36051145 DOI: 10.12998/wjcc.v10.i20.6759]
URL: https://www.wjgnet.com/2307-8960/full/v10/i20/6759.htm
Number Citing Articles
1
Sandip Mukherjee, Molee Chakraborty, Jake Haubner, Glen Ernst, Michael DePasquale, Danielle Carpenter, James C. Barrow, Anutosh Chakraborty. The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin SignalingBiomolecules 2023; 13(5): 868 doi: 10.3390/biom13050868
2
Evgenia Koureta, Evangelos Cholongitas. Evolving role of semaglutide in NAFLD: in combination, weekly and oral administrationFrontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1343587
3
Ahmed I. Gad, Nevin F. Ibrahim, Noura Almadani, Rasha Mahfouz, Hanaa A. Nofal, Dina S. El-Rafey, Hossam Tharwat Ali, Amr T. EL-Hawary, Ayman M. E. M. Sadek. Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled TrialDiseases 2024; 12(8): 186 doi: 10.3390/diseases12080186
4
Zeyu Xie, Sensen Yang, Weishang Deng, Jinjian Li, Jisheng Chen. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic ReviewClinical Epidemiology 2022; : 1463 doi: 10.2147/CLEP.S391819
5
Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic. MAFLD Pandemic: Updates in Pharmacotherapeutic Approach DevelopmentCurrent Issues in Molecular Biology 2024; 46(7): 6300 doi: 10.3390/cimb46070376